StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Cellectis Stock Performance
Shares of NASDAQ CLLS opened at $2.85 on Tuesday. The company has a market cap of $158.40 million, a P/E ratio of -1.66 and a beta of 3.08. The firm’s fifty day moving average is $2.74 and its two-hundred day moving average is $2.83. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.50 and a current ratio of 1.50. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77.
Cellectis (NASDAQ:CLLS – Get Free Report) last posted its earnings results on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share for the quarter. Cellectis had a negative net margin of 1,087.66% and a negative return on equity of 99.88%. The business had revenue of $1.99 million during the quarter. As a group, analysts anticipate that Cellectis will post -1.06 EPS for the current fiscal year.
Institutional Trading of Cellectis
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More
- Five stocks we like better than Cellectis
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- Health Care Stocks Explained: Why You Might Want to Invest
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- What is Forex and How Does it Work?
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.